平衡疗效、毒性与个体化：安维汀（enfortumab vedotin）用于晚期尿路上皮癌 - Suppr

Suppr

超能文献

Balancing effectiveness, toxicity, and individualization: enfortumab vedotin in advanced urothelial cancer.

作者信息

Wang Nuowei, Tully Karl H

机构信息

Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.

出版信息

Transl Androl Urol. 2025 Mar 30;14(3):503-506. doi: 10.21037/tau-2024-743. Epub 2025 Mar 26.

DOI:10.21037/tau-2024-743

PMID:40226067

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11986542/

Abstract

摘要

相似文献

Balancing effectiveness, toxicity, and individualization: enfortumab vedotin in advanced urothelial cancer.平衡疗效、毒性与个体化：安维汀（enfortumab vedotin）用于晚期尿路上皮癌

Transl Androl Urol. 2025 Mar 30;14(3):503-506. doi: 10.21037/tau-2024-743. Epub 2025 Mar 26.

Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.中国经治局部晚期或转移性尿路上皮癌患者的恩福妥昔单抗Vedotin Ⅱ期临床试验。

Cancer Med. 2024 Nov;13(21):e70368. doi: 10.1002/cam4.70368.

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.在铂类不耐受的晚期尿路上皮癌患者中，在使用PD-1或PD-L1抑制剂后使用恩杂鲁胺（EV‑201）：一项多中心、单臂、2期试验。

Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12.

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.尿路上皮癌的当前及新兴治疗方法：聚焦于恩杂鲁胺。（注：原文中药物名称有误，正确的药物名称是恩杂鲁胺，英文为Enzalutamide ，而Enfortumab Vedotin是恩沃利单抗，根据纠偏后的信息重新翻译了标题）正确的译文：尿路上皮癌的当前及新兴治疗方法：聚焦于恩沃利单抗。

Cancer Manag Res. 2023 Jul 18;15:699-706. doi: 10.2147/CMAR.S418009. eCollection 2023.

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.Enfortumab vedotin 治疗局部晚期或转移性尿路上皮癌日本患者的 I 期研究。

Invest New Drugs. 2020 Aug;38(4):1056-1066. doi: 10.1007/s10637-019-00844-x. Epub 2019 Aug 14.

Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.HIV 阳性患者膀胱癌使用恩福妥滨单抗偶联药物。

J Oncol Pharm Pract. 2022 Jul;28(5):1226-1229. doi: 10.1177/10781552221074309. Epub 2022 Jan 19.

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.在晚期尿路上皮癌中的有效性：来自调查治疗经验的尿路上皮癌网络（UNITE）研究的分析。

Cancer. 2022 Mar 15;128(6):1194-1205. doi: 10.1002/cncr.34057. Epub 2021 Dec 9.

Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.恩福妥单抗（enfortumab vedotin-ejfv）治疗晚期尿路上皮癌。

Expert Rev Anticancer Ther. 2022 May;22(5):449-455. doi: 10.1080/14737140.2022.2069563. Epub 2022 Apr 26.

Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.在接受恩杂鲁胺治疗转移性尿路上皮癌后发生的骨髓增生异常综合征。

IJU Case Rep. 2024 Jun 10;7(4):316-319. doi: 10.1002/iju5.12734. eCollection 2024 Jul.

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.在晚期尿路上皮癌患者中使用恩杂鲁胺+帕博利珠单抗治疗期间管理潜在不良事件。

Front Oncol. 2024 Apr 22;14:1326715. doi: 10.3389/fonc.2024.1326715. eCollection 2024.

本文引用的文献

Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer.药物-抗体偶联物 enfortumab-vedotin 和 sacituzumab-govitecan 在癌症靶向治疗中的副作用。

Cancer Epidemiol. 2024 Jun;90:102574. doi: 10.1016/j.canep.2024.102574. Epub 2024 Apr 23.

Eur Urol. 2024 Jun;85(6):574-585. doi: 10.1016/j.eururo.2024.01.007. Epub 2024 Feb 28.

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.厄达替尼与帕博利珠单抗治疗既往治疗的伴有特定 FGFR 改变的局部晚期或转移性尿路上皮癌患者的随机 III 期 THOR 试验：队列 2。

Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21.

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.ADC毒性机制及提高ADC耐受性的策略。

Cancers (Basel). 2023 Jan 24;15(3):713. doi: 10.3390/cancers15030713.

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.膜层粘连蛋白 4 的表达在尿路上皮癌转移过程中经常下降，并与恩福妥单抗 vedotin 的耐药性相关。

Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764.

Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.与 Nectin-4 定向抗体药物偶联物恩福妥昔单抗相关的皮肤事件的管理。

Oncologist. 2022 Mar 11;27(3):e223-e232. doi: 10.1093/oncolo/oyac001.

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System.与恩杂鲁胺相关的皮肤毒性：一项利用美国食品药品监督管理局不良事件报告系统的真实世界研究。

Front Oncol. 2022 Jan 19;11:801199. doi: 10.3389/fonc.2021.801199. eCollection 2021.

Patient-reported outcome measures (PROMs): A review of generic and condition-specific measures and a discussion of trends and issues.患者报告结局测量（PROMs）：通用和特定疾病测量工具的综述，以及对趋势和问题的讨论。

Health Expect. 2021 Aug;24(4):1015-1024. doi: 10.1111/hex.13254. Epub 2021 May 5.

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.TROPHY-U-01 研究：在铂类化疗和检查点抑制剂治疗后进展的转移性尿路上皮癌患者中 sacituzumab govitecan 的 II 期开放标签研究。

J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30.

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.恩福妥单抗 Vedotin 治疗既往治疗的晚期尿路上皮癌。

N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验